Everest Starts China Phase III Trial of Ulcerative Colitis Treatment
publication date: Nov 15, 2019
Everest Medicines, a New York biopharma that develops novel drugs for Greater China and Asia, has dosed the first patient in a China Phase III trial of etrasimod, a novel treatment for ulcerative colitis. In 2017, Everest in-licensed greater China rights to etrasimod from Arena Pharma of San Diego in a $224 million two-drug agreement. Everest was backed with $50 million in initial financing led by China's C-Bridge Capital and set up as a C-Bridge incubator platform for bringing novel drugs to China. More details....
Stock Symbol: (NSDQ: ARNA)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.